Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Common Equity (2021 - 2026)

Axsome Therapeutics' Common Equity history spans 6 years, with the latest figure at $54.6 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 2.6% to $54.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $54.6 million, a 2.6% increase, with the full-year FY2025 number at $88.3 million, up 54.86% from a year prior.
  • Common Equity hit $54.6 million in Q1 2026 for Axsome Therapeutics, down from $88.3 million in the prior quarter.
  • Over the last five years, Common Equity for AXSM hit a ceiling of $278.8 million in Q2 2023 and a floor of $14.7 million in Q1 2022.
  • Historically, Common Equity has averaged $111.0 million across 5 years, with a median of $92.9 million in 2024.
  • Biggest five-year swings in Common Equity: soared 1734.36% in 2023 and later crashed 70.15% in 2024.
  • Tracing AXSM's Common Equity over 5 years: stood at $109.6 million in 2022, then skyrocketed by 74.32% to $191.0 million in 2023, then crashed by 70.15% to $57.0 million in 2024, then skyrocketed by 54.86% to $88.3 million in 2025, then tumbled by 38.18% to $54.6 million in 2026.
  • Business Quant data shows Common Equity for AXSM at $54.6 million in Q1 2026, $88.3 million in Q4 2025, and $73.7 million in Q3 2025.